Micro heart lead shows promise in early test

NCT ID NCT04156412

Completed Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a very small, specially shaped heart lead (less than 2 French) in 39 adults getting a cardiac resynchronization therapy device. The goal was to see if the lead could successfully pace the left ventricle from two distant spots. Researchers measured pacing success, electrical performance, and any problems during the implant procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: new micro multipolar heart lead (device)
What this could lead to: If successful, this tiny lead could make cardiac resynchronization therapy more precise and easier to implant for heart failure patients.
What could go wrong: This is a very small, early pilot study with only 39 patients. The lead may not work better than standard leads, and there are risks from the implant procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC RESYNCHRONISATION THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC RESYNCHRONISATION THERAPY

Contacts and locations

Locations

Bordeaux University Hospital

Bordeaux, France
Clermont-Ferrand University Hospital

Clermont-Ferrand, France
Hospital Universitari Germans Trias i Pujol

Badalona, Spain
Hospital Universitario y Politécnico La Fe

Valencia, Spain
Lille University Hospital

Lille, France
Rennes University Hospital

Rennes, France
Rouen University Hospital

Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.